Sustained release fluoride composition
US4859467A · kind A · utility
7Cited by
10References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 1986 |
| Grant date | Aug 22, 1989 |
| Priority date | — |
| Expiry date | Sep 25, 2006 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge, tablet or capsule containing from 20 to 100 milligrams of sodium monofluorophosphate and further includes a slow release mechanism for controlling release of the fluoride ion over a period of up to eight hours after swallowing. Up to ten percent of sodium fluoride can be added.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.